Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
Trial details
- Registry ID
- NCT03755791
- Phase
- Phase 3
The FDA approved Sorafenib (Nexavar) on 1 Dec 2005.
Drug identity checked against registry records
Also recorded as Nexavar; Nexavar®
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer TherapyNCT03755791 | Exelixis | Phase 3 | Active not recruiting | 2021-11-30Actual |
| Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)NCT03606590 | NVCR | Phase 2 | Completed | 2021-01-14Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2005-12-01Day | Sorafenib | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA021923", "applicant_as_listed_by_fda": "BAYER HLTHCARE", "brand_names": ["NEXAVAR"], "active_ingredients": ["SORAFENIB TOSYLATE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20051201", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |